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Lipid Lowering and Alzheimer Disease
Risk: A Mendelian Randomization Study
Dylan M. Williams, PhD ,1,2 Chris Finan, PhD,3,4,5 Amand F. Schmidt, PhD,3,4,5,6
Stephen Burgess, PhD,7,8 and Aroon D. Hingorani, PhD, FRCP3,4,5
Objective: To examine whether genetic variation affecting the expression or function of lipid-lowering drug targets is
associated with Alzheimer disease (AD) risk, to evaluate the potential impact of long-term exposure to corresponding
therapeutics.
Methods: We conducted Mendelian randomization analyses using variants in genes that encode the protein targets of
several approved lipid-lowering drug classes: HMGCR (encoding the target for statins), PCSK9 (encoding the target for
PCSK9 inhibitors, eg, evolocumab and alirocumab), NPC1L1 (encoding the target for ezetimibe), and APOB (encoding
the target of mipomersen). Variants were weighted by associations with low-density lipoprotein cholesterol (LDL-C)
using data from lipid genetics consortia (n up to 295,826). We meta-analyzed Mendelian randomization estimates for
regional variants weighted by LDL-C on AD risk from 2 large samples (total n = 24,718 cases, 56,685 controls).
Results: Models for HMGCR, APOB, and NPC1L1 did not suggest that the use of related lipid-lowering drug classes
would affect AD risk. In contrast, genetically instrumented exposure to PCSK9 inhibitors was predicted to increase AD
risk in both of the AD samples (combined odds ratio per standard deviation lower LDL-C inducible by the drug tar-
get = 1.45, 95% confidence interval = 1.23–1.69). This risk increase was opposite to, although more modest than, the
degree of protection from coronary artery disease predicted by these same methods for PCSK9 inhibition.
Interpretation: We did not identify genetic support for the repurposing of statins, ezetimibe, or mipomersen for AD
prevention. Notwithstanding caveats to this genetic evidence, pharmacovigilance for AD risk among users of PCSK9
inhibitors may be warranted.
ANN NEUROL 2020;87:30–39
There are no preventive or disease-modifying treatmentsfor Alzheimer disease (AD). Expanding the indications of
drugs of proven efficacy into other indications might be an
effective strategy to provide new clinical treatments and pre-
ventative medicines for AD.1 Opportunities for indication
expansion should be widespread, considering arguments based
on first principles,2 and empirical evidence from genome-wide
association studies (GWASs) showing that the same gene can
influence risk of more than one disease (pleiotropy).3
Medications that decrease circulating low-density
lipoprotein cholesterol (LDL-C), such as statins, have been
proposed as candidate therapies for AD. Hyperlipidemia in
midlife is a risk factor for late onset AD in prospective epi-
demiological studies,4 and associations of higher LDL-C
with increased cerebral β-amyloid load have also been
observed in autopsy and in vivo imaging studies.5,6 Simi-
larly, AD risk is lower among statin users, and this associa-
tion appears to be more pronounced with longer treatment
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25642
Received May 29, 2019, and in revised form Nov 11, 2019. Accepted for publication Nov 11, 2019.
Address correspondence to Dr Williams, MRC Unit for Lifelong Health and Ageing at UCL, University College London, 1-19 Torrington Place, 5th Floor,
London, WC1E 7HE, United Kingdom. E-mail: dylan.williams@ucl.ac.uk
From the 1Medical Research Council Unit for Lifelong Health and Ageing at University College London, University College London, London, United
Kingdom; 2Department of Medical Epidemiology & Biostatistics, Karolinska Institute, Stockholm, Sweden; 3Institute of Cardiovascular Science, Faculty of
Population Health, University College London, London, United Kingdom; 4Health Data Research UK, London, United Kingdom; 5British Heart Foundation
University College London Research Accelerator, London, United Kingdom; 6Department of Cardiology, Division Heart and Lungs, University Medical
Center Utrecht, Utrecht, the Netherlands; 7Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom; and
8Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
Additional supporting information can be found in the online version of this article.
© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.30
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited.
exposure and the use of more potent drugs.7 In contrast,
corresponding observational data on other lipid-lowering
drug classes are scant and inconclusive.7 Large randomized
controlled trials (RCTs) may help to clarify the effects of
dyslipidemia treatments on AD incidence without con-
founding, but such evidence is limited,8 and the slowly
evolving pathogenesis of AD (over at least 1 decade)9,10
means it is ill-suited as an endpoint in trials of lipid-
lowering drugs with relatively short periods of intervention
and follow-up (typically 2–5 years).
Genetic epidemiology provides another means to
address these questions. The expression or function of pro-
tein drug targets can be influenced by variants within or near
the genes that encode them, and the genetic effects can be
used to anticipate the effects of drug action.11 Because geno-
types are inherited randomly at conception in an analogous
manner to treatment allocation in clinical trials, associations
of variants with biomarkers and disease outcomes are not
expected to be subject to biases from confounding and
reverse causation seen in other types of observational
epidemiology—a principle leveraged in an approach known
as “Mendelian randomization” (MR).12 Moreover, geno-
types are mostly anticipated to confer lifelong differences in
traits. Hence, MR studies can help to guide drug target vali-
dation by predicting the consequences of long-term thera-
peutic exposure.13 In this study, we examined whether AD
risk is influenced by variation in the genes encoding the tar-
gets of a range of medications that are currently licensed and
recommended for the treatment of primary or familial
hypercholesterolemia to prevent coronary heart disease.
Subjects and Methods
Study Design
We used a 2-sample MR study design for these analyses,14 based
mainly on genetic variants located in or near genes that encode the
relevant drug targets (cis-MR).13 We first identified differences in
circulating LDL-C that are associated with single nucleotide poly-
morphisms (SNPs) at the genomic regions of interest in sets of
publicly available genetic association summary statistics, because
the lowering of LDL-C in circulation is a major, established physio-
logical response produced by the use of the lipid-lowering therapeu-
tics. We then combined the LDL-C association statistics for variant
sets with corresponding genome-wide association statistics for AD
risk from 2 large, independent case–control datasets, to predict the
effects of drug use on AD development.
As depicted in the study overview (Fig 1), we performed
5 main MR analyses: one assessing the effect of a general reduc-
tion of LDL-C on AD risk (ie, achievable by any means), and
the remainder for specific effects of variation at 4 gene regions
(HMGCR, PCSK9, APOB, and NPC1L1) that are indicative of
the long-term use of different lipid-lowering drug classes that are
currently licensed and guideline-supported for lowering LDL-C
in the primary prevention of coronary heart disease, familial
hypercholesterolemia, or both. These genes encode the targets of
statins (HMG-CoA reductase [HMGCR]), proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors (eg, evolocumab and
alirocumab), apolipoprotein B-100 (ApoB) antisense classes (eg,
mipomersen), and NPC1-like intracellular cholesterol transporter
1 (NPC1L1) inhibitors (eg, ezetimibe), respectively.
In post hoc analyses to follow up on genetic analyses model-
ing PCSK9 inhibition in relation to AD risk that were weighted by
LDL-C, we also examined whether genetically indexed variation in
circulating PCSK9 concentration is associated with AD risk.
Deriving SNP Associations with LDL-C
SNP–LDL-C association statistics were extracted from 3 GWASs
of circulating LDL-C concentrations—2 from the Global Lipid
Genetics Consortium15,16 and 1 from the MAGNETIC consor-
tium.17 These contained different sets of genotyped and imputed
SNP data and varying sample sizes, and hence estimated any
genetic effect with varying precision. Due to partial overlap
between the GWAS samples, the 3 sets of estimates were
appended together, rather than combined in a meta-analysis to
prevent double counting (see Fig 1). Where the same SNP–
LDL-C associations were present in more than one GWAS
dataset, we retained the estimate from the largest of the samples.
In combining these sets of GWAS summary statistics, we aimed
to leverage the maximum degree of genetic variation measured at
each region (optimizing statistical power to detect associations of
regional variation with AD risk). The sample sizes for SNP–
LDL-C association statistics ranged from 14,004 to 295,826.
Each of the LDL-C GWASs had homogeneous samples (all of
European ancestry) and was modeled with consistent statistical
procedures and transformations of the LDL-C distributions.
For general LDL-C models, we used independent SNPs
throughout the genome that had replicated evidence for associa-
tion with LDL-C in any of the 3 GWAS datasets. We excluded a
SNP in APOE on chromosome 19 due to a strong, established
pleiotropic effect of this locus on AD risk, and another variant on
chromosome 19 that exhibited linkage disequilibrium (LD) with
the SNPs that constitute the ε2/3/4 genotypes in APOE. A total
of 59 SNPs remained after LD clumping (steps described further
in the Statistical Analysis section) and were taken forward to har-
monize with AD data. In primary gene region models, we
extracted data on all SNPs within 1 kilobase in either direction of
the start and stop coordinates for the genes, according to Human
Genome reference release GRCh37 positions. In secondary models
for gene regions, we expanded the selection to all SNPs within
100 kilobases of the genes’ coordinates. Data on the beta coeffi-
cients, standard errors, coded effect, and alternate alleles and allele
frequencies per SNP were extracted to combine with summary sta-
tistics from the AD datasets.
Analyses to assess the effect of modifying circulating
PCSK9 on AD risk were based on SNP–PCSK9 association sta-
tistics for 6 variants identified in a GWAS of circulating PCSK9
in suspected or confirmed coronary artery disease (CAD) patients
of European ancestry.18 We used SNP–PCSK9 association statis-
tics from a subgroup analysis of statin-naive participants in the
GWAS (n = 2,022).
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AD Data
We assessed whether LDL-associated variants also associate with
late onset AD risk (age of onset ≥65 years) using data from
2 large genome-wide analyses from the International Genomics
of Alzheimer’s Project (IGAP) and the Psychiatric Genomics
Consortium (PGC).19,20 The total sample size was 24,718 cases
and 56,685 controls, all of whom had European ancestry (sum-
mary details are given in Table 1). Full information on genetic
quality control procedures and association modeling are provided
in the study references.19,20
Positive Control Analyses
To help validate the chosen modeling strategy, we also merged
the same sets of LDL-C summary statistics with genetic data on
the risk of CAD and type 2 diabetes mellitus (T2D), for which
we may expect to see effects of LDL-C modification (ie, positive
control analyses). These models used summary GWAS data on
CAD risk from the CARDIoGRAM consortium (n = 22,233
cases, 64,762 controls)21,22 and T2D risk from the DIAGRAM
consortium (n = 12,171 cases, 56,862 controls).22 Samples
included participants of European ancestry only.
Statistical Analysis
Data for SNP associations with LDL-C or PCSK9 and with risk
of AD or cardiometabolic outcomes were harmonized to match
coded effect alleles consistently; we excluded ambiguous SNPs
from analyses (those with palindromic genotypes and minor
allele frequencies between 0.4 and 0.5).
FIGURE 1: Study overview. Black lines depict an illustrative gene region, with raised boxes showing exons. Wedges represent
the presence of specific genetic variants (single nucleotide polymorphisms [SNPs]) measured throughout the gene. Different
patterns of the wedges illustrate the combination of sources of low-density lipoprotein cholesterol (LDL-C) association statistics
across variants from 1 of 3 LDL-C genome-wide association studies (GWASs; second and third panels). The pairing of wedges
above and below the gene outline in panel 4 depicts the harmonization of appended LDL-C statistics with corresponding
estimates of Alzheimer disease (AD) risk for each variant within the 2 AD datasets separately. The varying number of wedges
present across each dataset represents the differences in densities of SNPs that were genotyped or imputed in the data.
GLGC = Global Lipid Genetics Consortium; IGAP = International Genomics of Alzheimer’s Project; PGC = Psychiatric Genomics
Consortium.
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To assess a potential effect of LDL-C lowering on AD,
regardless of drug target, we used the fixed-effects inverse vari-
ance weighted (IVW) meta-analysis method, which combines
ratios of coefficients (Wald estimators) for the association esti-
mates of each eligible SNP with LDL-C and AD.23 We repeated
analyses using alternative methods—weighted median and MR
Egger estimators—which provide different degrees of robustness
to bias from genetic pleiotropy.24,25
For the primary gene (drug target)-specific models, data on
all successfully harmonized SNPs within the gene regions (1
kilobase flank) were eligible for inclusion. We then used LD
clumping to remove the excess of most highly correlated variants
at each locus (with pairwise r2 values >0.6), retaining the member
of each correlated pair with the lowest p value for association with
LDL-C. Remaining SNPs were modeled together using a principal
components (PC)-based approach to handle estimates from corre-
lated variants.26 This method relies on the use of reference data to
estimate the correlations between variants in summary GWAS
datasets, for which we used correlation matrices derived from
503 participants of European ancestry in the 1000 Genomes pro-
ject, phase 3.27 We tested the robustness of using these reference
data by inputting several matrix types from different subpopula-
tions of the 1000 Genomes project sample, including the actual
correlations from the PGC data. We also tested the consistency of
PC estimates by specifying 3 values of κ (0.9, 0.99, and 0.999),
which would be expected to model between 90 and 99.9% of var-
iance in LDL-C attributable to genetic variants in each gene
region (results from the 99% models are presented in each
figure).26 For comparison, we also conducted analyses for gene
region models with a wider range of SNPs for inclusion (within
100 kilobases of the genes), and with MR estimates provided by
the IVW method to enroll only independent SNPs with GWAS
significant associations with LDL-C (SNP–LDL association
p values <5 × 10−8). Independence between SNPs was defined by
pairwise r2 values <0.2 in one set of models, and then repeated
with SNPs clumped using a more conservative threshold
(r2 < 0.01). Funnel plots were produced to test whether overall
MR estimates were consistent with the estimates provided by the
most precise individual SNP estimators, and leave-one-out plots
were produced to examine whether models were influenced by
any individual outlying SNP estimates.28 Using LD-clumped vari-
ants, we also conducted MR Egger and weighted median models
for any gene region–AD variant set that included 3 or more SNPs.
We also conducted both PC and LD-clumped gene region models
for analyses of cardiometabolic outcomes.
For both general LDL-C and gene (drug target)-specific
models, we opted to analyze effects on AD risk separately in the
2 AD GWAS datasets, due to these having varying SNP data
available and different sample structures (a mix of matched case–
control studies, samples from longitudinal cohorts, and health
care register–derived samples). Finally, we combined the 2 results
for each trait–AD association into overall MR estimates using
fixed-effects IVW meta-analyses. Results were scaled to express
odds ratios (ORs) for AD and cardiometabolic outcomes per
TABLE 1. Summary Information on AD Datasets
Study
IGAP19 PGC20
Cases, n 21,982 2,736
Controls, n 41,944 14,741
Sample sources Case–control studies, longitudinal
cohorts
Register-based follow-up of twin cohorts/
case–control DemGene study
Country of origin Europe, Canada, USA Sweden/Norway
Case mean AAO, yra 71.1–82.6 77.0–80.5
Control mean AAE, yra 51.0–78.9 58.8–75.5
% female, cases/controls 59.3–67.3/51.8–60.6 52.5–66.4/48.0–51.1
AD ascertainment Clinical assessment, MRI- or
autopsy-confirmed, and/or diagnoses
from health care records
Clinical assessment and/or diagnoses from
health care records
Genetic data Genome-wide genotyping, imputation
using 1000 Genomes project, phase 2
release
Genome-wide genotyping, imputation using
1000 Genomes project, phase 3 release
aRanges of mean or percentage values are presented for IGAP stage 1 and PGC data, which combined 4 consortia/studies and 3 samples in these
genome-wide association studies, respectively.
AAE = age at examination or last follow-up; AAO = age at onset; AD = Alzheimer disease; IGAP = International Genomics of Alzheimer’s Project;
MRI = magnetic resonance imaging; PGC = Psychiatric Genomics Consortium.
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1 standard deviation (SD) lower LDL-C, to indicate the expected
directions of effect that would follow from the use of lipid-
lowering drugs.
Post hoc analyses for circulating PCSK9 involved the same
steps and MR methods used to model the effect of a general
LDL-C lowering on AD risk. Again, we also estimated the effects
of lowering PCSK9 on CAD for comparison. Because SNP–
PCSK9 associations were expressed in logn-transformed PCSK9
units, results from these MR models were scaled to show CAD
and AD risk differences per halving of circulating PCSK9.
Analyses were undertaken in Stata version 15 (StataCorp,
College Station, TX), PLINK 1.9 (www.cog-genomics.org/plink/
1.9/), and R version 3.4.1, with the aid of the packages MR Base
and MendelianRandomization.29,30
This research involved the reuse of existing anonymized,
study-level summary data only. All of the original studies had
received informed consent from participants and ethical approvals.
Results
After harmonizing exposure (LDL-C or PCSK9) and dis-
ease outcome genetic associations, and subsequent LD
clumping, main MR models included between 2 and
55 variants (Supplementary Tables 1–5).
A general, long-term reduction in circulating LDL-C,
indexed using eligible variants throughout the genome, was
not estimated to affect AD risk (Fig 2). Findings were also
null in alternate MR analyses using weighted median and
MR Egger methods (Table 2), and these findings did not
suggest any notable bias from directional pleiotropy or
weak instruments in these models; for example, in analyses
of the IGAP dataset, the MR Egger intercept test was 1.00
(p = 0.39), with I2gx of 98.7% in both datasets.
Gene region models using the PC-based approach for
HMGCR, APOB, and NPC1L1 did not provide clear evi-
dence to suggest that the use of the corresponding lipid-
lowering drug classes would affect AD risk (see Fig 2).
Results for these regions were largely consistent when
repeated with IVW models; all point estimates for HMGCR
were on the side of neuroprotection and all estimates for
APOB and NPC1L1 were on the side of risk, but confidence
intervals (CIs) in all instances were wide and included the
null. In contrast, variants in the vicinity of PCSK9 implied
that exposure to PCSK9 inhibitors could increase the risk of
AD (OR = 1.45, 95% CI = 1.23–1.69, p = 4.4 × 10−6).
Estimates were similar in meta-analyses of IVW models with
liberal clumping (OR = 1.37, 95% CI = 1.12–1.66) and
conservative clumping (OR = 1.44, 95% CI = 0.94–2.20).
There was no evidence of heterogeneity between estimates
from the 2 AD samples (p values for heterogeneity tests in
FIGURE 2: Meta-analysis of Mendelian randomization estimates for Alzheimer disease (AD) risk according to a lifelong reduction
in circulating low-density lipoprotein cholesterol (LDL-C) and exposure to the modulation of several related drug targets
(n = 24,718 cases, 56,685 controls). The first group of results shows estimates for the effect of a general, long-term reduction of
LDL-C (achievable by any means) on AD risk. The second to fifth group labels are representative of genetic variation at gene
regions (HMGCR, PCSK9, APOB, and NPC1L1) that predict the effects of specific therapeutic target modulation, followed by
example drug classes that affect these targets. CI = confidence interval; IGAP = International Genomics of Alzheimer’s Project;
OR = odds ratio; PGC = Psychiatric Genomics Consortium; SD = standard deviation; SNP = single nucleotide polymorphism.
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all models ≥0.11). Funnel plots did not indicate asymmetry
in SNP estimates across the scale of precision in IVW
models, and leave-one-out plots did not suggest that any of
the IVW findings were greatly influenced by single outlying
Wald estimators (plots available on request). MR Egger and
weighted median results for LD-clumped variant sets are
shown in Supplementary Table 6. In general, these did not
deviate greatly from IVW findings, but most estimates were
very imprecise (particularly those from MR Egger). Point
estimates varied widely between IVW, weighted median,
and MR Egger methods for PCSK9 inhibition and AD risk
in IGAP data, but were more consistent in the PGC dataset.
Sensitivity analyses indicated that the choice of refer-
ence data used to model variant correlations would not be
expected to influence findings from PC models notably.
ORs for the effects of PCSK9 inhibition on AD risk in the
PGC sample ranged from 1.64 (95% CI = 1.17–2.31) per
SD lower LDL-C using allele frequencies from a sample
with Finnish ancestry to 1.73 (95% CI = 1.12–2.66) using
allele frequencies of samples with ancestries from across
Europe. In comparison, the corresponding estimate using
the sample’s actual allele frequencies was 1.69 (95%
CI = 1.14–2.52). Changing input parameters for PC
models introduced some slight variation in the magnitudes
of estimates. For example, using κ = 0.90 or κ = 0.999
instead of 0.99 in PC models (ie, enrolling either 90% or
99.9% of variance in LDL-C concentrations attributable to
genetic variation in the gene region) yielded meta-analysis
TABLE 2. MR Estimates for the Effect of LDL-C Lowering on AD Risk in IGAP and PGC Datasets
Study Method Odds Ratio 95% CI p
IGAP IVW 0.98 0.88–1.10 0.75
MR Egger 1.04 0.88–1.22 0.67
MR Egger intercept test 1.00 0.99–1.00 0.39
Wtd median 0.95 0.82–1.11 0.53
PGC IVW 1.01 0.74–1.38 0.96
MR Egger 1.41 0.89–2.25 0.15
MR Egger intercept test 0.98 0.96–1.00 0.06
Wtd median 1.19 0.81–1.75 0.38
IVW results are illustrated in the top section of Figure 2. Odds ratios and 95% CIs are per 1 standard deviation lower LDL-C. IGAP and PGC models
included 54 and 55 single nucleotide polymorphisms, respectively.
AD = Alzheimer disease; CI = confidence interval; IGAP = International Genomics of Alzheimer’s Project; IVW = inverse variance weighted;
LDL-C = low-density lipoprotein cholesterol; MR = Mendelian randomization; PGC = Psychiatric Genomics Consortium; Wtd = weighted.
FIGURE 3: Mendelian randomization estimates for the effects of exposure to drug target modulation on coronary artery disease
(CAD) and type 2 diabetes mellitus (T2D). Results were produced using variants within gene regions (1 kilobase flanks) and the
principal components–based method, as per analyses for the Alzheimer disease results presented in Figure 1. Sample sizes:
CAD, n = 22,233 cases, 64,762 controls; T2D, n = 12,171 cases, 56,862 controls. CI = confidence interval; LDL-C = low-density
lipoprotein cholesterol; OR = odds ratio; SD = standard deviation; SNP = single nucleotide polymorphism.
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effect estimates for PCSK9 inhibition on AD risk of 1.35
(95% CI = 1.09–1.67) and 1.62 (95% CI = 1.41–1.86),
respectively. Despite these varying magnitudes of estimates,
the use of different PC model permutations would not
change the overall interpretation of these findings.
Using the same approach to predict the effects of
long-term modulation of these targets on cardiometabolic
outcomes (positive control models), genetically predicted
exposures to all lipid-lowering drug classes were associated
with a lower risk of CAD (Fig 3). There were trends for
increased risk of T2D with predicted exposure to statins
and inhibitors of PCSK9 and NPC1L1 (as has been
observed previously31,32), although results from NPC1L1
variants were estimated with limited precision.
Given the finding that genetic indexing of PCSK9
inhibition predicted higher AD risk in our main models,
we further examined whether differences in exposure to
circulating PCSK9 may be related to AD risk using MR,
and compared these results to the predicted effect of circu-
lating PCSK9 variation on CAD (Table 3). As expected,
lowering PCSK9 concentration (which correlates modestly
with lower circulating LDL-C) was predicted to reduce
CAD risk. In IVW models for AD, point estimates from
IGAP and PGC were both on the side of risk per halving
of circulating PCSK9, but the IGAP sample result and the
meta-analysis finding both included the null. Point esti-
mates from MR Egger and weighted median methods
were very similar to IVW estimates from both AD
samples, but the findings had very little precision due to
the use of few available SNPs to index PCSK9 differences.
Discussion
This MR study did not identify support for the
repurposing of statins, or medications that inhibit
NPC1L1 or block ApoB production, to delay or prevent
AD onset. Our results also raise the possibility (but in no
way confirm) that exposure to PCSK9 inhibitors might
predispose individuals to AD, although with the magni-
tude of relative risk observed being smaller than for the
estimated degree of protection from CAD.
If the use of lipid-lowering medications in general
does not affect AD risk, this may signify the absence of a
substantial role of primary hypercholesterolemia in AD
etiology. The only major RCT to have addressed the effect
of therapeutic LDL-C reduction on dementia risk to date
found equal incidence (0.3%) in both simvastatin and
placebo-allocated arms after 5 years of follow-up (albeit in
a sample aged 40–80 years at baseline, thus including
many individuals too young to be at risk of late onset
AD).33 Taking this finding alongside no prominent
genetic associations observed for general LDL-C lowering
(as others have observed previously),34,35 and unclear or
null results for HMGCR and 2 other drug targets, sug-
gests that previous prospective observational associations
of hyperlipidemia with AD, and of higher LDL-C with
TABLE 3. MR Estimates for the Effect of Lowering PCSK9 on CAD and AD Risk
Study SNPs, n Method Odds Ratio 95% CI p
CAD 2 IVW 0.57 0.36–0.89 0.01
IGAP 3 IVW 1.10 0.85–1.43 0.47
MR Egger 1.10 0.67–1.81 0.78
MR Egger intercept test 1.00 0.93–1.07 0.99
Wtd median 1.09 0.81–1.47 0.56
PGC 3 IVW 1.98 1.02–3.81 0.04
MR Egger 1.95 0.58–6.54 0.48
MR Egger intercept test 1.00 0.84–1.19 0.98
Wtd median 1.72 0.81–3.65 0.16
AD meta-analysis 3 IVW 1.19 0.94–1.51 0.16
Odds ratios and 95% CIs are per halving of circulating PCSK9 concentrations.
AD = Alzheimer disease; CAD = coronary artery disease; CI = confidence interval; IGAP = International Genomics of Alzheimer’s Project;
IVW = inverse variance weighted; MR = Mendelian randomization; PGC = Psychiatric Genomics Consortium; SNP = single nucleotide polymor-
phism; Wtd = weighted.
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AD-related neuropathology, may have been overstated due
to residual confounding. Associations of lipid-lowering
drug use with AD risk would also be prone to bias via
confounding by indication.36
A previous analysis has also addressed whether varia-
tion at HMGCR and PCSK9 is associated with AD risk
using MR.37 After excluding pleiotropic variation at APOE,
the authors found no association of a genetically predicted
reduction in LDL-C exposure with AD in a sample that
overlaps with one of those in the current analyses
(a previous IGAP GWAS from 2013).38 Their result using
HMGCR and PCSK9 variation (combined in a single IVW
model) from IGAP data had a consistent direction and sim-
ilar magnitude of association as in our findings, but con-
flated the potentially independent associations of the
different gene regions with AD, and may have lacked preci-
sion due to the use of fewer variants and a smaller sam-
ple.37 Using a more comprehensive survey of genetic
variation at PCSK9 separately in 2 large AD datasets, our
analyses yielded consistent estimates of higher AD risk from
lower PCSK9 function, regardless of the MR method used.
We also report tentative MR evidence to suggest that lower
circulating PCSK9 might reduce AD risk, although these
findings were inconclusive, because the precision of the
models was limited by the use of few variants with which
to proxy exposure to PCSK9 concentrations.
Considering the full range of our findings together, if
PCSK9 function has a role in determining AD risk, this is
likely to be through pathways other than the regulation of
peripheral LDL-C. Experimental evidence has linked
PCSK9 dysfunction to cerebral β-amyloid production and
neuronal cell death—both hallmarks of AD.39 PCSK9 may
also promote neurogenesis during development,40 so any
impact on AD risk could potentially be mediated by esta-
blishing “brain reserve” in early life,41 as opposed to a has-
tening of AD pathogenesis in adulthood. However,
concerns of adverse neurocognitive effects of PCSK9 inhibi-
tion have been raised from a network meta-analysis of
RCTs of PCSK9 inhibitors in middle-aged and older indi-
viduals.42 Another MR analysis has also suggested poten-
tially detrimental effects of lower PCSK9 function on
cognitive ability in a cohort of participants aged 38 to
73 years.43 A further consideration is whether PCSK9 inhi-
bition might harm the cerebral vasculature (independently
of effects on atherosclerosis). Cerebrovascular damage might
influence AD neurodegeneration directly,44 or affect risk
estimates if AD case samples include misclassified vascular
(or mixed) dementia patients. However, other MR studies
and RCTs have found conflicting evidence of the relation-
ship of PCSK9 inhibition with stroke risk,26,45,46 and we
have no knowledge of evidence implicating PCSK9 func-
tion in cerebral small vessel disease or vascular dementia.
Given that PCSK9 inhibitors are an efficacious
second-line drug class for the treatment of primary hyper-
cholesterolemia and mixed dyslipidemia, we present these
suggestive findings cautiously. We note that the point esti-
mates from the much larger sample (IGAP) were less pro-
nounced than those from the smaller sample across the
various types of models, although several estimates from
IGAP were still of a concerning magnitude individually.
Moreover, when considering SNPs with the greatest evi-
dence of functional relevance in the PCSK9 region, such as
the rare missense variant rs11591147, genotype–AD associ-
ations were on the side of higher risk per LDL-lowering
allele but were not statistically significant individually in
either dataset or when meta-analyzed. Further genetic stud-
ies can help to confirm or refute these results in several
ways, including (1) repeating MR models of PCSK9 func-
tion in larger GWASs of AD risk, which would ideally
include direct genotyping of functionally relevant SNPs in
the PCSK9 gene region; (2) assessing the associations of
PCSK9 variants with AD endophenotypes, for example,
from large-scale GWASs of fluid and/or imaging bio-
markers of β-amyloid load; and (3) recall-by-genotype stud-
ies to examine the presence of subclinical AD pathologies
and symptoms in older individuals carrying loss- or gain-of-
function PCSK9 mutations. Because PCSK9 inhibitors
have been licensed since 2015 in several territories,
pharmacoepidemiologic studies of the consequences of
PCSK9 inhibitor use versus other lipid-lowering agents for
AD risk could also be conducted with large samples of indi-
viduals in national or insurance-based prescription registers,
as could the follow-up of AD risk differences among past
participants in PCSK9 inhibitor trials.
The principal strength of this study was the use of
2 large AD samples in which to test for the consistency,
and improve the precision, of MR estimates. The merging
of LDL-C summary statistics and use of methodology to
combine correlated variation in MR models allowed us to
predict the effects of manipulating drug targets more pre-
cisely, even when using variants solely within gene regions.
Using cis-acting variants alone should be less prone to bias
from horizontal pleiotropy than the use of variation across
wide flanking regions, because there is a higher probability
of SNPs incidentally tagging AD risk variants elsewhere in
the genome with increasing physical distance from the
gene encoding a target of interest.
Limitations include the prediction solely of on-target
effects of drug use by our models; they do not encapsulate
off-target consequences of using the related therapeutic
classes. Second, genetics may not be informative about par-
ticular pharmacological aspects of drug exposure. For
instance, monoclonal antibodies, such as evolocumab and
alirocumab, are not expected to cross the blood–brain
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barrier (at least while the barrier’s impermeability to large
molecules is intact).47 Hence, peripherally administered
PCSK9 inhibitors may not lead to cerebral exposure, which
means the genetically-instrumented risk might not be rele-
vant in therapeutic practice. Analogous circumstances have
been examined for T2D, where evidence from human
genetics suggests reduced PCSK9 activity leads to greater
diabetes risk, but there is no clear evidence to show that
this risk increase has borne out among RCT participants
exposed to PCSK9 inhibitors.31,48 The disparities may be
reconciled if localized PCSK9 function in pancreatic tissue
were to affect glycemic control independently of any inhibi-
tion of PCSK9 in circulation, as has been suggested by data
from tissue-selective Pcsk9 knockout mice.49 If data from
larger GWASs of circulating PCSK9 become available,
improved MR analyses of circulating PCSK9 concentra-
tions and AD risk (ie, using multiple genome-wide SNPs
to index differences in exposure) would help to evaluate the
role of peripheral PCSK9 inhibition specifically. Third,
given that genetic effects are often lifelong, we cannot dis-
tinguish critical periods of exposure to these targets in
which disease risk might be specifically affected, such as
neurodevelopment. Fourth, differences between the IGAP
and PGC samples are also worth noting; in particular, a
modest proportion of AD cases in the PGC sample were
diagnosed from linkage to in- and outpatient health care
records after the latest clinical assessments of these individ-
uals were conducted (up to 741 cases, 27% of the PGC
case sample). Individuals with other forms of dementia may
have been misclassified as AD cases, or AD cases as con-
trols, at higher rates with this type of ascertainment than in
case–control or cohort studies with direct clinical assess-
ments and/or pathological confirmation of AD.50 This
could bias exposure–outcome association estimates if the
exposures under study relate to the chance of mis-
classification differentially, for example, if an exposure
increases the risk of hospitalization and, therefore, raises the
likelihood of AD detection. However, this would not be
expected to explain an inverse association of a trait affecting
CAD risk with lower AD risk, as we observe for PCSK9
variation. Furthermore, a large majority of the cases in the
PGC sample, as well as IGAP, were diagnosed reliably with
AD at memory clinics according to standard criteria.
Conclusions
Evidence from this study does not support RCTs to inves-
tigate the repurposing of statins, or inhibitors of
NPC1L1- or ApoB-blocking therapeutics, for AD preven-
tion. Notwithstanding the several caveats discussed here,
pharmacovigilance for neurocognitive effects and the scope
for increased AD burden in users of PCSK9 inhibitors
may be warranted.
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